TORONTO, Jan. 14, 2013 (GLOBE NEWSWIRE) -- Gemoscan Canada, Inc. (TSX-V:GES) (MUN:1GE) ("Gemoscan" or the "Company"), a leading owner and marketer of food sensitivity and dietary management solutions, wishes to congratulate its Chief Naturopath and Naturopathic Advisor, Mubina Jiwa, N.D., on being recently awarded a Leadership Pin by Naturopathic Doctors Ontario ("NDO").
In 2011, to mark their 60th Anniversary, NDO began a new tradition of awarding Leadership Pins to NDs and Corporate Partners who in the course of their years as members or over the past year have provided their leadership to the association. This honour was bestowed upon Dr. Jiwa in recognition of her providing valuable leadership and expertise to the NDO organization in 2012.
"The Leader Pin is a significant award given to influential Naturopathic Doctors who are members of Naturopathic Doctors Ontario, and who have provided valuable leadership and expertise to our association," said Elias Markou, Chair of NDO.
Dr. Jiwa has been with Gemoscan since 2007. Previously, she was Associate Professor, and is now Assistant Professor, at the Canadian College of Naturopathic Medicine. She is a member of Naturopathic Doctors Ontario and is registered with the Board of Directors of Drugless Therapy - Naturopathy. Dr. Jiwa has collaborated on nutrition-related research projects at the University of British Colombia and on research projects at the British Colombia Children's Hospital. Dr. Jiwa's program on immuno food intolerances has been accredited by the Canadian Council on Continuing Education in Pharmacy. Dr. Jiwa also manages a private practice in the Greater Toronto Area.
"On behalf of every member of the Gemoscan family, I would like to congratulate Dr. Jiwa on this wonderful achievement. Her expertise and integrity are clearly evident in all aspects of her professional life. I am personally honored to be associated with Dr. Jiwa and look forward to her ongoing guidance as we continue to build upon Gemoscan's leadership position in the emerging food intolerance industry," said Brian Kalish, Gemoscan's President and Chief Executive Officer.
About Gemoscan Canada, Inc.
Gemoscan is an industry leader in food intolerance management and maintains a first-to- market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology, Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODE™ Food Intolerance System and the MenuWise™ Food Intolerance Plan, personalized naturopathically supervised nutritional programs that promote well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available.
Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.
Forward-Looking Information
This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward- looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.